New Assays to Measure Immunosuppressive Drugs Now Available

These two assays complement the currently available Elecsys Tacrolimus and Cyclosporine assays, and with the mycophenolic acid (MPA) assay complete the Roche Diagnostics immunosuppressive drug monitoring portfolio.

The Elecsys family of assays offer performance based on Roche’s proven Elecsys heterogeneous immunoassay electrochemiluminescence (ECL) technology. The tests can be performed on any of the cobas modular platforms, including the cobas 4000 and cobas 6000 analyzer series, or the high-volume cobas 8000 modular analyzer series.

“Immunosuppressive drug monitoring requires a high level of precision to ensure that patients receive the optimal therapy. The new Elecsys ISD Assays will offer reliable, life-long testing to patients who have had organ transplants,” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “This full offering also provides clinical laboratories with the opportunity to optimize their workflows and consolidate testing for a wide range of relevant markers on a single platform. This is a further example of the Roche commitment to invest in personalized healthcare”.

Related Links:
Roche